Explore Business Standard
Widely used heart disease risk calculators may be failing to identify a large proportion of Indians at risk, with nearly 80 per cent of patients who eventually suffered a heart attack not being classified as 'high-risk' beforehand, according to new research. The research titled "Comparison of ASCVD Risk Prediction Models in STEMI: Insights from a South Asian Cohort" was conducted by a team of scientists from Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, ESIC Medical College, Faridabad, the Delhi Cancer Registry at AIIMS, among others. The study, conducted on 4,975 patients with first-time heart attacks, found significant differences in how five major global risk prediction models categorised individuals, raising concerns over their reliability for South Asian populations. Researchers compared widely used tools such as the Framingham Risk Score (FRS), ACC/AHA ASCVD 2013 model, WHO risk charts, JBS-3 calculator and the newer Predicting Risk of ...
Cardiovascular diseases remain the leading cause of mortality in India, causing nearly 31 per cent of deaths, according to the latest data presented by the Sample Registration Survey under the Registrar General of India. The Report on Causes of Death: 2021-2023, issued on Wednesday, said non-communicable diseases are the leading causes of death in the country, constituting 56.7 per cent of all deaths. "Communicable, maternal, perinatal and nutritional conditions constitute another 23.4 per cent of deaths. In the 2020-2022 (affected by COVID) period, the corresponding values were 55.7 per cent and 24.0 per cent, respectively," it said. The report said that overall cardiovascular disease remained the leading cause of death, claiming nearly 31 per cent of lives, followed by respiratory infections at 9.3 per cent, malignant and other neoplasms at 6.4 per cent, and respiratory diseases at 5.7 per cent. The cardiovascular diseases, a lifestyle phenomenon, are the leading cause in the ...
Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent ...